Sign in to follow
Search Results

0 results for 'Sanofi SA'

You can use to get even better search results
March 28, 2013 |

The Spinmeister: David Lam | Wachtell, Lipton, Rosen & Katz

Splitting Abbott Labs in half was an undertaking of historic proportions: The Wachtell team had to spin off and finance a brand-new $54 billion pharma giant.
18 minute read
April 05, 2005 |

Merger Plagued by Patent Challenges

A year ago this month, French pharmaceuticals company Aventis SA succumbed to a $69.1 billion takeover by its smaller Gallic rival Sanofi-Synth�labo SA after Paris intervened to fend off a Swiss interloper. Investors and analysts are still debating whether that move resulted in a sensible merger or was a political faux pax. A key to that answer lies in American courts, where Sanofi-Aventis SA faces patent challenges to its three biggest-selling drugs.
5 minute read
September 14, 2009 |

Federal Circuit Hands Sanofi-Aventis Win in Fight Over Generic Cancer Drug

Sanofi-Aventis SA has taken its share of licks in its long-running battle with drug makers selling generic versions of Eloxatin, a drug used to treat colon cancer. Last month, the U.S. Food and Drug Administration approved the generic drugs for sale despite an appellate ruling granting Sanofi a stay of a district court order that found the generics did not infringe Sanofi's patents. But Sanofi finally got some good news on Thursday when the Federal Circuit vacated the lower court's ruling and remanded the case.
3 minute read
August 30, 2010 |

Genzyme rejects Sanofi-Aventis offer

Biotechnology company Genzyme Corp. said today it rejected Sanofi-Aventis SA's $18.5 billion buyout offer because it undervalues the company.
2 minute read
Federal Circuit Reverses Lower Court, Hands Sanofi-Aventis Win in Fight over Generic Versions of Cancer Drug
Publication Date: 2009-09-10
Practice Area:
Industry:
Court:
Judge:
Attorneys:
For plaintiff:
For defendant:
Case number:

The appellate ruling comes too late to keep generic manufacturers of the colon cancer drug Eloxatin out of the market, but the Federal Circuit found that a lower court judge interpreted Sanofi's patent incorrectly when he cleared the way for its rivals.

August 15, 2006 |

Bristol-Myers, Sanofi-Aventis File Injunction to Stop Sales of Generic Plavix

Bristol-Myers Squibb and Sanofi-Aventis have filed an injunction against Apotex to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. In the filing, the two brand-name makers listed several reasons the injunction should be issued, including the likelihood they will win the pending patent case and that Apotex's launch last week is causing them irreparable harm. They also said they have begun discounting Plavix to stem the loss of the drug's market share.
2 minute read
November 11, 2005 |

Company Relents on Drug News Web Site

An Internet newsletter devoted to the anti-obesity drug Acomplia can keep its Web site address now that it has settled with the drug's maker, Sanofi-Aventis SA. Medical Week News Inc. launched AcompliaReport.com last year to track the progress of the drug as it goes through clinic trials and awaits approval from the U.S. Food and Drug Administration. But Sanofi-Aventis asked an international arbitrator to force Medical Week to relinquish the site name, saying it could confuse the public.
2 minute read
January 04, 2010 |

Big Deals

The largest recent transactions, all worth at least €500 million, involving targets or acquirors from each of six European jurisdictions or regions: United Kingdom, Spain, Italy, Germany, France, and Scandinavia.
5 minute read
August 15, 2006 |

Bristol-Myers, Sanofi-Aventis File Injunction to Stop Sales of Generic Plavix

Bristol-Myers Squibb and Sanofi-Aventis have filed an injunction against Apotex to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. In the filing, the two brand-name makers listed several reasons the injunction should be issued, including the likelihood they will win the pending patent case and that Apotex's launch last week is causing them irreparable harm. They also said they have begun discounting Plavix to stem the loss of the drug's market share.
2 minute read
April 05, 2005 |

David Katz: Frequent Flyer

2 minute read

TRENDING STORIES

    More from ALM

    More from ALM

    Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

    Resources

    • Revenue, Profit, Cash: Managing Law Firms for Success

      Brought to you by Juris Ledger

      Download Now

    • Law Firm Operational Considerations for the Corporate Transparency Act

      Brought to you by Wolters Kluwer

      Download Now

    • The Ultimate Guide to Remote Legal Work

      Brought to you by Filevine

      Download Now

    • Practical Guidance Journal: Protecting Work Product in a Generative AI World

      Brought to you by LexisNexis®

      Download Now